Hypertension: Competing Treatments and Market Entry Considerations

Questions: Discounts, Updates etc.

Pages: 225

Price (Single): £5900

Price (Departmental): £8850

Price (Company): £11800

Publication Date: 2010-06-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Today, approximately 1 billion people worldwide have high blood pressure, a figure expected to increase to 1.5 billion by 2025, affecting 1 in 3 adults over the age of 20 (Lancet. 2005;365:217-223). Hypertension is commonly seen in developing as well as developed countries and, where it remains untreated, presents a major risk factor for heart attack, stroke, kidney failure and other cardiovascular diseases.

In a field where therapies are often unsatisfactory, physicians seek to extent their understanding and use of available treatments to improve patient outcomes. Knowledge in these areas is also important to drug developers, who seek a better understanding of prescribing practices and treatment needs and limitations from the clinician’s perspective, as part of their own efforts to develop more effective therapies. To meet interest in these areas, Biopharm Reports has conducted a global survey on current treatments and drug prescribing practices for Hypertension. This survey involved the participation of more than 280 clinical centres in 50 countries. In addition to drugs directly used to treat Hypertension (e.g. Diuretics, Calcium Channel Blockers), other drugs commonly prescribed to hypertensive patients (e.g. Statins), were also surveyed. See Clinical Survey, below.

Overview

  • A global study of treatments and drug prescribing practices for Hypertension
  • The participation of more than 280 physicians in 51 countries.
  • Leading participant countries were the USA, Italy, Greece, Argentina Canada, China and Spain
  • 98% of study participants are practicing physicians and 71% are specialists in Hypertension treatment
  • Of the participating organisations, 32% were hospital specialist hypertension departments, 18% were hospital general departments, 18% were specialist hypertension practices, 6% were private hypertension clinics and 3% were general practices. Others participants were specialised in areas such as cardiology and nephrology.
  • The diagnosis of eight Hypertension sub-types
  • Single or multiple drugs used to treat hypertension
  • Treatments and prescribing practices for 9 different drugs classes used to treat Hypertension
  • Diuretics: prescribing practices covering 16 different drugs
  • Beta Blockers and Alpha Blockers: prescribing practices covering 23 different drugs
  • Adrenergic Receptor Agonists: prescribing practices covering 4 different drugs.
  • Calcium channel blockers: prescribing practices covering 14 different drugs.
  • ACE Inhibitors: prescribing practices covering 12 different drugs.
  • Angiotension II Receptor Antagonists: prescribing practices covering 7 different drugs.
  • Statins: prescribing practices covering 6 different drugs
  • Aldosterone antagonists: prescribing practices covering 2 different drugs.
  • Drug combinations: prescribing practices involving the combined use of 9 different drug classes in the treatment of hypertension.
  • Combined drug formulations: Prescribing practices based on the use of 20 different combined drug formulations in the treatment of hypertension
  • Issues and challenges in the treatment of Hypertension: clinician's perspective 

Clinical Survey

  • Organisation. Hospital General Department, Hospital Specialist Hypertension Department, Specialist Hypertension Practice, Private Hypertension Clinic, General Practice or other (specified).
  • Physicians. Specialist physician in Hypertension treatment, General physician or other (specified).
  • Hypertension Diagnosis: Estimated percentage of patients with normal blood pressure or diagnosed with Prehypertension, Stage 1 Hypertension, Stage 2 Hypertension, Isolated Systolic Hypertension, Resistant Hypertension, Drug-induced Hypertension, Pregnancy-related Hypertension, Exercise-related Hypertension or other secondary Hypertension (specified).
  • Single or Multiple Drugs. Estimated  percentage  of patients prescribed a single drug, two or more different drug classes taken together (e.g. two different tablets), combined drug formulations (two or more different drugs in one formulation) or other (specified).
  • Drug Classes. Estimated percentage of patients who are prescribed Diuretics, Beta Blockers (adrenergic receptor antagonists), Alpha Blockers (adrenergic receptor antagonists), Adrenergic Receptor Agonists, Calcium Channel Blockers, ACE Inhibitors, Angiotensin II Receptor Antagonists, Statins, Aldosterone Antagonists, Centrally Acting Antihypertensives, Vasodilators or other (specified).
  • Diuretics. Estimated percentage of patients prescribed ethacrynic acid (Edecrin®, loop diuretic), torsemide (Demadex®, loop diuretic), furosemide (Lasix®, loop diuretic), bumetanide (Bumex®, loop diuretic), epitizide (epitizide®, thiazide diuretic), bendroflumethiazide (Aprinox®; Neo-NaClex®, thiazide diuretic), metolazone (Mykrox®, Zaroxolyn®, thiazide-like diuretic), hydrochlorothiazide (Esidrix®, HydroDIURIL®, thiazide diuretic), indapamide (Lozol®, thiazide-like diuretic), chlorthalidone (Hygroton®, thiazide-like diuretic), chlorothiazide (Diuril®, thiazide-like diuretic), amiloride (Midamor®, Amilamont®, potassium-sparing diuretic), spironolactone (Aldactone®, potassium-sparing diuretic), triamterene (Dyrenium®,potassium-sparing diuretic), triamterene/hydrochlorothiazide (HCTZ) (Maxzide®, Dyazide®, combined diuretic formulation), furosemide/spironolactone (e.g. Osyrol-Lasix®) or other (specified).               
  • Beta Blockers and Alpha Blockers. Estimated percentage of patients prescribed the following Beta Blockers or Alpha Blockers, for the treatment of Hypertension: atenolol (e.g. Tenormin®, Tenormine®, Prenormine®, Atenol®, beta blocker), metoprolol (e.g. Betaloc-SA®, Lopresor®, Lopresor SR®, beta blocker), nadolol (e.g. Corgard®, beta blocker), Nebivolol (Nebilet®, beta blocker), oxprenolol (e.g. Slow-Trasicor®; Trasicor®, beta blocker), pindolol (e.g. Visken®, Betapindol®, Calvisken®, Decreten®, beta blocker), propranolol, (e.g. Inderal®, Inderal LA®, Beta-Prograne®, beta blocker), carvedilol (Coreg®, beta blocker), bisoprolol (e.g. Cardicor®,Concor®) timolol (e.g. Blocadren®, beta blocker), ebivolol (e.g. Nebilet®), acebutolol (e.g. Sectral®, beta blocker), betaxolol (e.g. Kerlone®, beta blocker), carteolol (e.g. Cartrol®, beta blocker), penbutolol (e.g. Levatol®, beta blocker),   doxazosin (e.g. Cardura®,Carduran®, alpha blocker), phentolamine (e.g Regitine®, alpha blocker), indoramin (e.g. Doralese®, alpha blocker), phenoxybenzamine (e.g. Dibenzyline®, alpha blocker), prazosin(e.g. Hypovase®, alpha blocker), terazosin (e.g Hytrin®, Hytrin BPH®, alpha blocker), carvedilol (e.g. Coreg®, mixed alpha and beta blocker), labetalol (e.g. Normodyne®, Trandate®, mixed alpha and beta blocker) or other (specified).
  • Adrenergic Receptor Agonist. Estimated percentage of patients prescribed the following adrenergic receptor agonists, for the treatment of Hypertension: Options: clonidine (e.g. Catapres®, Catapres-TTS-1®, Catapres-TTS-2®, Duraclon®), methyldopa (e.g. Aldomet®, Apo-Methyldopa®, Dopamet®, Novomedopa®), rilmenidine (e.g. Hyperium®), guanfacine (e.g. Tenex®), other. If other, please specify.
  • Calcium Channel Blockers. Estimated percentage of patients prescribed the following calcium channel blockers, for the treatment of  ypertension: Options: nimodipine (e.g. Nimotop®), diltiazem (e.g. Cardizem®, Dilacor®), amlodipine (e.g. Norvasc®), felodipine (e.g. Plendil®), isradipine (e.g. DynaCirc®), verapamil (e.g. Calan®, Isoptin®, Verelan®), manidipine (e.g. Iperten®), nisoldipine (e.g. Sular®), nicardipine (e.g. Cardene®), nifedipine (e.g. Adalat®, Procardia®), lercanidipine (e.g. Zanidip®) lacidipine (e.g. Lacipil®,Motens®), nitrendipine (e.g. Nitrepin®), Clevidipine (e.g. Cleviprex®) or other (specified).  
  • ACE Inhibitors. Estimated percentage of patients prescribed ACE inhibitors, for the treatment of Hypertension: Options: captopril        (e.g. Capoten®), enalapril (e.g. Vasotec®), quinapril (e.g. Accupril®), benazepril (e.g. Lotensin®), cilazapril (e.g. Vascace®), ramipril (e.g. Altace®), perindopril (e.g. Aceon®) lisinopril (e.g. Prinivil®, Zestril®), fosinopril (e.g. Staril®), trandolapril (e.g Gopten®), imidapril (e.g. Tanatril®), moexipril (e.g. Univasc®) or others (specified).
  • Angiotension II Receptor Antagonists. Estimated percentage of patients prescribed the following angiotensin II receptor antagonists, for the treatment of Hypertension: losartan (e.g. Cozaar®, Hyzaar®), olmesartan (e.g. Benicar®), candesartan (e.g. Atacand®), telmisartan (e.g. Micardis®), eprosartan (e.g. Teveten®), irbesartan (e.g. Avapro®), valsartan (e.g. Diovan®) or others (specified).
  • Statins. Estimated percentage of patients prescribed statins, for the treatment of Hypertension: Options: atorvastatin (e.g.Lipitor®), fluvastatin (e.g.Lescol®), lovastatin (e.g.Mevacor®), pravastatin (e.g.Pravachol®), simvastatin (e.g. Zocor®), rosuvastatin e.g.Crestor®) or others (specified).
  • Aldosterone Antagonists. Estimated percentage of patients prescribed the following aldosterone antagonists, for the treatment of Hypertension: Options: eplerenone (e.g.Inspra®), spironolactone (e.g. Aldactone®, Verospiron®) or others (specified)
  • Centrally Acting Antihypertensive Drugs. Estimated percentage of your patients who are prescribed the following centrally acting drugs, for the treatment of Hypertension: Options: clonidine (e.g.Catapres®), guanfacine (e.g.Tenex®), Guanabenz (e.g.Wytensin®), methyldopa (e.g.Aldomet®), rilmenidine (Hyperium®), moxonidine (Physiotens®) or others (specified).
  • Other drugs. Estimated percentage of patients prescribed the following centrally acting drugs, for the treatment of Hypertension: clonidine (e.g.Catapres®), guanfacine (e.g.Tenex®), Guanabenz (e.g.Wytensin®), methyldopa (e.g.Aldomet®), rilmenidine (Hyperium®), moxonidine (Physiotens®) or others (specified).
  • Drug Combinations.  1st, 2nd and 3rd most frequently used combinations of individual drugs classes used for the treatment of Hypertension (i.e where two or more different drugs (e.g. two different tablets) are prescribed for use by the patient at the same time). Drugs classes considered include Diuretics, Beta blockers, Alpha blockers, Adrenergic receptor agonists, Calcium channel blockers, ACE inhibitors, Angiotensin II receptor antagonists, Statins, Aldosterone antagonists or others (specified).
  • Combined Drug Formulations. Estimated percentage of patients prescribed co-formulated or combined drugs for the treatment of Hypertension including the options clonidine hydrochloride/chlorthalidone (e.g. Clorpres®), captopril/ hydrochlorothiazide tablets (e.g. Capozide®), spironolactone/hydrochlorothiazide (e.g. Aldactazide®), triamterene/hydrochlorothiazide (e.g. Dyazide®), valsartan/hydrochlorothiazide (e.g. Diovan HCT®), amlodipine/atorvastatin (e.g. Caduet®), telmisartan/hydrochlorothiazide (HCTZ) (e.g. Micardis HCT®), irbersartan/hydrochlorothiazide (HCTZ) (e.g. Avalide®,CoAprovel®), trandolapril/verapamil (e.g Tarka®), enalapril/hydrochlorothiazid (e.g. Vaseretic®), amlodipine/valsartan (e.g. Exforge®), olmesartan/amlodipine (e.g. Azor®), aliskiren/hydrochlorothiazide (HCTZ))(e.g. Tekturna HCT®), amlodipine/benazepril (e.g. Lotrel®), Olmesartan Medoxomil / Hydrochlorothiazide (e.g. Benicar HCT), losartan/hydrochlorothiazide (e.g. Hyzaar®), perindopril/amlodipine, delapril/manidipine, lercanidipine/enalapril, lisinopril/amlodipine or others (specified).
  • Challenges and Issues in the treatment of Hypertension: clinician's perspective

Table of Contents

1.       Introduction 5
2.       Hypertension Therapy Survey 7
3.       Survey Participants 14
4.       Diagnosis (Sub-Types) 26
5.       Single or Multiple Drugs 38
6.       Drug Classes 43
7.       Diuretics 57
8.       Beta and Alpha Blockers 71
9.       Adrenergic Receptor Agonists 87
10.     Calcium Channel Blockers 95
11.     ACE Inhibitors 106
12.     Angiotension II Receptor Antagonists 116
13.     Statins 123
14.     Aldosterone Antagonists  130
15.     Centrally Acting Drugs 135
16.     Other Drugs 142
17.     Drug Combinations 147
18.     Combined Drug Formulations 158
19.     Study Participants 172
Appendix 1 182

Figures

Tables


Appendix 1. Responses provided by study participants to the question: What are the major issues and challenges associated with the treatment of Hypertension? Responses given by physicians to this question (which in some cases may be brief, informal or abbreviated) are presented verbatim, except in those some cases where minor grammatical or typographical corrections have been made for reasons of clarity.

Other users found this report page using the following search terms: Hypertension hypertension formulation guanfacine valsartan hyzaar lasix furosemide vs marketed physiotens

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.